Rallybio Corp — Investor Relations & Filings
Filings indexed
246
across all filing types
Latest filing
2026-05-13
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
RLYB
Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | |
| 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | |
| S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | |
| 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 45759935 | 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | ||
| 40888387 | 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | ||
| 36271286 | S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | ||
| 32897547 | 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | ||
| 32897544 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | ||
| 32897545 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English | ||
| 32897546 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-20 | English | ||
| 31541794 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31541795 | 8-K Filing | 2026-01-29 | English | ||
| 13111487 | DEF 14A | 2026-01-02 | English | ||
|
2025
5 filings
| |||||
| 13111488 | PRE 14A | 2025-12-23 | English | ||
| 13111490 | 10-Q | 2025-11-06 | English | ||
| 13111494 | 8-K | 2025-11-06 | English | ||
| 13111491 | 8-K | 2025-08-29 | English | ||
| 13111493 | 10-Q | 2025-08-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
WOOJUNG BIO, Inc.
Offers pre-clinical CRO services, research facility enginee…
|
215380 | KR | Professional, scientific and te… |
|
WuXi AppTec Co., Ltd.
Global CRDMO enabling pharma and life sciences to accelerat…
|
2359 | CN | Professional, scientific and te… |
|
Xceleron Inc.
Specialist provider of ultra-sensitive bioanalytical servic…
|
— | CA | Professional, scientific and te… |
|
XEROS TECHNOLOGY GROUP PLC
Develops and licenses polymer-based solutions that reduce i…
|
XSG | GB | Professional, scientific and te… |
|
Xilio Therapeutics, Inc.
A clinical-stage biotech developing tumor-activated immuno-…
|
XLO | US | Professional, scientific and te… |
|
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD
Pharmaceutical R&D and CRO services for drug discovery and …
|
600721 | CN | Professional, scientific and te… |
|
Xintela AB
Biomedical company developing stem cell therapies for regen…
|
XINT | SE | Professional, scientific and te… |
|
Xlife Sciences AG
Develops and commercializes early-stage life sciences resea…
|
XLS | CH | Professional, scientific and te… |
|
XtalPi Holdings Limited
Accelerates molecular R&D using AI, quantum physics, and ro…
|
2228 | KY | Professional, scientific and te… |
|
Y-Biologics, Inc
Develops antibody-based therapeutics for cancer, focusing o…
|
338840 | KR | Professional, scientific and te… |
Rallybio Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34901/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34901 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34901 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34901 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34901}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Rallybio Corp (id: 34901)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.